Immix Net Income Per Share from 2010 to 2026

IMMX Stock  USD 7.33  0.10  1.35%   
Immix Biopharma Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to -0.72 in 2026. During the period from 2010 to 2026, Immix Biopharma Net Loss regression line of annual values had significance of  0.31 and arithmetic mean of (0.78). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(0.69)
Current Value
(0.72)
Quarterly Volatility
1.5249866
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 49.6 K, Net Interest Income of 1.2 M or Depreciation And Amortization of 139.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.44. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Immix Stock
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.
The evolution of Net Income Per Share for Immix Biopharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Immix Biopharma compares to historical norms and industry peers.

Latest Immix Biopharma's Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Immix Biopharma over the last few years. It is Immix Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Pretty Stable
   Net Income Per Share   
       Timeline  

Immix Net Income Per Share Regression Statistics

Arithmetic Mean(0.78)
Coefficient Of Variation(194.55)
Mean Deviation0.70
Median(0.29)
Standard Deviation1.52
Sample Variance2.33
Range6.4917
R-Value(0.26)
Mean Square Error2.31
R-Squared0.07
Significance0.31
Slope(0.08)
Total Sum of Squares37.21

Immix Net Income Per Share History

2026 -0.72
2025 -0.69
2024 -0.76
2023 -0.89
2022 -0.59
2021 -6.64
2020 -0.15

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(0.69)(0.72)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.